Biostream is developing a urine-based diagnostic platform for early detection and monitoring of neurodegenerative diseases such as Parkinson’s, Alzheimer’s, and MS.

At the core is a nanotech-enhanced lateral flow assay (LFA) that detects brain-specific biomarkers in urine. The strip is designed in a multi-line “barcode” format, producing a semi-quantitative result using gold nanoparticles for enhanced sensitivity. Results appear within minutes.

A smartphone app scans and interprets the strip using the phone’s camera, correcting for lighting and device differences. It displays results as categorized biomarker levels (e.g., low, elevated) and stores data securely for ongoing trend analysis.

An integrated AI engine combines strip data with patient history to deliver real-time risk alerts. It personalizes interpretation based on baseline levels and detects early warning signs—even before clinical symptoms emerge—supporting physicians in timely intervention decisions.

Biostream combines nanotech, mobile health, and AI into a scalable, non-invasive tool for proactive neurological care.